Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONNECTION PLUS open-label extension of dimebon in Alzheimer's disease
NL-OMON33439Phase 3Active, not recruiting
- Sponsor
- Medivation
- Start
- Aug 2009
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of latrepirdine in Alzheimer's disease (AD), sponsored by Medivation. Primary endpoints: Adverse events, Vital signs and 9 more. Started Aug 2009; status: active, not recruiting.
02
Drugs
latrepirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON33439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33439.